文献速递糖尿病肥胖与代谢综合征

胃旁路术与袖状胃切除术对2型糖尿病缓解、体重减轻及心血管危险因素5年影响的比较(Oseberg):单中心、三盲、随机对照试验的次要结局

Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-04-01

这项在挪威公共三级肥胖中心开展的单中心、三盲、随机对照试验的5年次要结局分析显示,在合并2型糖尿病的肥胖成人中,胃旁路术在2型糖尿病缓解、体重减轻和LDL胆固醇降低方面优于袖状胃切除术,但症状性餐后低血糖更多见。

要点

  • 胃旁路术组2型糖尿病缓解率高于袖状胃切除术组(HbA1c≤6.0%:50% vs 20%)。
  • 胃旁路术组体重减轻和LDL胆固醇降低幅度均大于袖状胃切除术组。
  • 胃旁路术组症状性餐后低血糖发生率高于袖状胃切除术组(28% vs 2%)。

核心结论

  • 胃旁路术在2型糖尿病长期缓解、体重减轻和LDL胆固醇浓度方面优于袖状胃切除术,但以症状性餐后低血糖发生率更高为代价。

研究设计与样本

  • 两臂、单中心、三盲、随机对照试验的次要分析,在挪威一家公共三级肥胖中心开展。
  • 年龄≥18岁、合并2型糖尿病和肥胖的成人按1:1随机分配至腹腔镜胃旁路术或袖状胃切除术,区组大小为10。
  • 研究 personnel、参与者和主要结局评估者在术后1年内对分组设盲,此后随访为开放标签。
  • 2012年10月15日至2017年9月1日期间评估319例患者资格,最终109例参与者被随机分配至胃旁路术(n=54)或袖状胃切除术(n=55)。
  • 基线平均年龄47.7岁(SD 9.6),平均BMI 42.3 kg/m2(SD 5.3),女性72例(66%),男性37例(34%)。

主要发现

  • 93例(85%)参与者完成5年随访(袖状胃切除术组47例[85%],胃旁路术组46例[85%])。
  • 胃旁路术组2型糖尿病缓解比例高于袖状胃切除术组:HbA1c≤6.0%为46例中23例(50%)vs 44例中9例(20%),风险差29.5%(95%CI 10.8至48.3)。
  • 胃旁路术组2型糖尿病缓解比例高于袖状胃切除术组:HbA1c<6.5%为29例(63%)vs 13例(30%),风险差33.5%(95%CI 14.1至52.9)。
  • 胃旁路术组体重减轻大于袖状胃切除术组:平均22.2%(95%CI 20.3至24.1)vs 17.2%(95%CI 15.3至19.1),治疗差异5.0%(95%CI 2.4至7.7)。
  • 胃旁路术组LDL胆固醇降低大于袖状胃切除术组:治疗差异-0.5 mmol/L(95%CI -0.8至-0.1)。

关键数值与推荐

  • 2型糖尿病缓解定义为HbA1c≤6.0%时,胃旁路术组46例中23例(50%)vs 袖状胃切除术组44例中9例(20%),风险差29.5%(95%CI 10.8至48.3)。
  • 2型糖尿病缓解定义为HbA1c<6.5%时,胃旁路术组29例(63%)vs 袖状胃切除术组13例(30%),风险差33.5%(95%CI 14.1至52.9)。
  • 体重减轻:胃旁路术组平均22.2%(95%CI 20.3至24.1)vs 袖状胃切除术组17.2%(95%CI 15.3至19.1),治疗差异5.0%(95%CI 2.4至7.7)。
  • LDL胆固醇治疗差异为-0.5 mmol/L(95%CI -0.8至-0.1),胃旁路术组低于袖状胃切除术组。
  • 糜烂性食管炎和Barrett食管的患病率两组相似,而病理性酸反流在袖状胃切除术组更常见(风险差51.1%[95%CI 28.0至74.2])。

临床怎么用

  • 作者认为这些发现可为临床实践和未来指南中关于2型糖尿病患者首选手术方式的制定提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For individuals with obesity and type 2 diabetes, weight loss improves insulin sensitivity and β-cell function and can induce remission of diabetes. However, the long-term comparative effectiveness of standard gastric bypass and sleeve gastrectomy on remission of type 2 diabetes remains unclear. We aimed to compare the effects of gastric bypass and sleeve gastrectomy on type 2 diabetes remission, weight loss, and cardiovascular risk factors 5 years after surgery. METHODS: We present a secondary analysis of a two-armed, single-centre, triple-blind, randomised controlled trial conducted at a public tertiary obesity centre in Norway. Adults (ie, age ≥18 years) with type 2 diabetes and obesity were randomly assigned (1:1) by a computerised random number generator to laparoscopic gastric bypass or sleeve gastrectomy, with balanced block sizes of ten. Study personnel, participants, and the primary-outcome assessor were all masked to the allocation until 1 year after surgery, after which further follow-up was open label. Changes in key secondary outcomes, including type 2 diabetes remission, weight loss, and cardiovascular risk factors, were assessed 5 years after surgery. The trial procedure estimand assessed treatment effects in all randomised participants, with data collected after conversional surgery removed from analyses. The trial was registered with ClinicalTrials.gov (NCT01778738) and was completed in December, 2022. FINDINGS: Between Oct 15, 2012, and Sept 1, 2017, 319 patients were assessed for eligibility, resulting in 109 participants who were randomly assigned to gastric bypass (n=54) or sleeve gastrectomy (n=55). The baseline mean age was 47·7 years (SD 9·6), mean BMI 42·3 kg/m2 (SD 5·3), 72 (66%) were women, and 37 (34%) were men. 93 (85%) participants completed 5-year follow-up (47 [85%] in the sleeve gastrectomy group and 46 [85%] in the gastric bypass group). The proportions with remission of type 2 diabetes were higher after gastric bypass than after sleeve gastrectomy (HbA1c ≤6·0% 23 [50%] of 46 vs nine [20%] of 44, risk difference 29·5% [95% CI 10·8 to 48·3]; HbA1c <6·5% 29 [63%] vs 13 [30%], risk difference 33·5% [14·1 to 52·9]). Gastric bypass provided greater loss in bodyweight (mean 22·2% [95% CI 20·3 to 24·1] vs 17·2% [15·3 to 19·1], treatment difference 5·0% [2·4 to 7·7]) and lower LDL-cholesterol (treatment difference -0·5 mmol/L [-0·8 to -0·1]). The prevalence of erosive oesophagitis and Barrett's oesophagus was similar between groups, whereas pathological acid reflux occurred more frequently after sleeve gastrectomy (risk difference 51·1% [28·0 to 74·2]). More participants had symptomatic postprandial hypoglycaemia after gastric bypass than after sleeve gastrectomy (15 [28%] vs one [2%]). INTERPRETATION: Gastric bypass was superior to sleeve gastrectomy regarding long-term remission of type 2 diabetes, weight loss, and LDL cholesterol concentrations, at the expense of a higher frequency of symptomatic postprandial hypoglycaemia. These findings could inform clinical practice and future guidelines regarding the preferred surgical procedure in patients with type 2 diabetes. FUNDING: Vestfold Hospital Trust. TRANSLATION: For the Norwegian translation of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Wågen Hauge J, Borgeraas H, Birkeland KI, et al. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2025. PMID: 40185112. doi:10.1016/S2213-8587(24)00396-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。